Adenoid Cyctic Carcinoma (ACC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Adenoid cystic carcinoma (ACC) is a rare type of malignant neoplasm that develops within secretory glands, most commonly the head and neck major and minor salivary glands. The trachea, lacrimal gland, breast, skin, and vulva are other sites of origin. The histologic appearance of this neoplasm distinguishes it. Adenoid cystic carcinoma has been reported in many age groups, including cases in the pediatric age group. Most people are diagnosed with the disease in their fourth to sixth decade of life. The definitive whole genome and exome sequencing has greatly improved our understanding of the pathogenesis of ACC. A balanced translocation derived from the MYB-NFIB fusion gene appears to be an essential feature of ACC. In addition, sequencing identified several other driver genes that are mutated in common downstream pathways in other well-studied cancers.

Description

A rare type of malignant neoplasm called adenoid cystic carcinoma (ACC) develops in secretory glands, most frequently the major and minor salivary glands of the head and neck. The vulva, breast, skin, lacrimal gland, and trachea are additional sites of origin. The histologic appearance of this neoplasm distinguishes it. Tumors of the lacrimal glands can cause proptosis or changes in vision. Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Those affecting the trachea or larynx may cause respiratory symptoms or speech changes, respectively. Because ACC often spreads along nerves, advanced tumors can cause pain and/or nerve paralysis. It can also be spread through blood. In about 5 to 10% of cases, it spreads to the lymph nodes. The etiology of ACC is currently unknown. It usually doesn't work at home.

Adenoid cystic carcinoma (ACC)- (Epidemiology)

Adenoid cystic carcinoma (ACC) is a rare cancer that typically affects the salivary glands. With a slight female predominance (60% vs. 40%), head and neck ACC has an age-adjusted incidence rate of 4.5 cases per 100,000 people. The average age at head and neck ACC diagnosis is roughly 57 years old, though this varies depending on the primary cancer site. After initial treatment, ACC has a propensity for delayed recurrence and metastasis as well as an indolent clinical course. At long-term follow-up, nearly half of patients died from ACC as opposed to other causes, with five, ten, and fifteen-year survival rates after surgical resection reported as 77.3%, 59.6%, and 44.9%, respectively. Adenoid cystic carcinoma has been reported in many age groups, including cases in the pediatric age group. Most people are diagnosed with the disease in their fourth to sixth decade of life. As in all cancers studied to date, genomic DNA damage occurs during the development of ACC. The pathophysiology of ACC is still poorly understood, which leads to fewer evidence-based treatments than for other cancers due to its rarity and unique clinical features.

Adenoid cystic carcinoma (ACC)-Current Market Size & Forecast Trends

ACC, being a rare malignancy, represents a smaller market size of around $160 million in 2023. This value is expected to increase to about USD 260.7 million by 2033, reflecting a compound annual growth rate (CAGR) of around 5.0% during this period. Growth is driven by advancements in precision oncology and targeted therapies. Overall, the ACC market is well-positioned for growth through 2035, as new therapies and improved diagnostic methods continue to emerge.

The knowledge of the pathogenesis of ACC has been greatly enhanced by the definitive whole genome and exome sequencing. An important characteristic of ACC appears to be a balanced translocation derived from the MYB-NFIB fusion gene. Sequencing also uncovered several additional driver genes that are altered in typical downstream pathways in additional well-researched cancers. Additionally, oncoproteins necessary for angiogenesis, cell growth, adhesion, and cell cycle regulation are overexpressed by ACC. These studies typically identify therapeutic genes and proteins based on the tumor phenotype rather than the target mechanisms of non-specific cytotoxic agents. Additionally, immunotherapy may be effective, despite the fact that there is currently little research on ACC. The initial development of immunotherapies to enhance new targeted drug treatments and outcomes in ACC patients will be made easier by a better understanding of genetics. Genetic mutations and biomarkers for ACC have been found through a number of studies. Balanced transduction of homozygous viral myeloid oncogenic factor I/B (MYB-NFIB) is one of them and is a typical molecular event of avian tumorigenesis. In their 2009 study, Pearson et al. MYB-NFIB fusion gene seizures were observed frequently in ACC samples. The MYB gene is dysregulated as a result of the T (6; 9) chromosomal translocation (q22-23; p23-24), which produces chimeric transcripts containing MYB and NFIB. Apoptosis, cell adhesion, and cell cycle regulation are three important downstream cellular processes that are disrupted as a result of MYB's constitutively active activation of its target genes. Recent whole-genome sequencing and the ACC exome have revealed some new, compelling data. him and other people. DNA samples from normal people were combined with 60 tumor cells to analyze the tumor sequences.

Report Highlights

Adenoid Cyctic Carcinoma (ACC)- Current Market Trends

Adenoid Cyctic Carcinoma (ACC) - Current & Forecasted Cases across the G8 Countries

Adenoid Cyctic Carcinoma (ACC) - Market Opportunities and Sales Potential for Agents

Adenoid Cyctic Carcinoma (ACC) - Patient-based Market Forecast to 2035

Adenoid Cyctic Carcinoma (ACC) - Untapped Business Opportunities

Adenoid Cyctic Carcinoma (ACC) - Product Positioning Vis-a-vis Competitors' Products

Adenoid Cyctic Carcinoma (ACC) - KOLs Insight